# Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

Study · id `cardio:ct-nct07820111` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07820111](<https://clinicaltrials.gov/study/NCT07820111>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07820111

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT07820111. Randomized; no masking; primary purpose treatment. Start 2025-10-18 (actual); primary completion 2026-03-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT07820111, source copy `cardio:ctgov-nct07820111-2026-09-15`, retrieved 2026-10-26)
- Started: 2025-10-18 (actual) (ClinicalTrials.gov record NCT07820111, source copy `cardio:ctgov-nct07820111-2026-09-15`, retrieved 2026-10-26)
- Primary completion: 2026-03-17 (actual) (ClinicalTrials.gov record NCT07820111, source copy `cardio:ctgov-nct07820111-2026-09-15`, retrieved 2026-10-26)
- Completion: 2026-03-17 (actual) (ClinicalTrials.gov record NCT07820111, source copy `cardio:ctgov-nct07820111-2026-09-15`, retrieved 2026-10-26)
- Countries: Saudi Arabia (ClinicalTrials.gov record NCT07820111, source copy `cardio:ctgov-nct07820111-2026-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07820111-2026-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
- Condition: Obese Diabetics
- Condition: Obese Non Diabetic
- Intervention (Drug): Dulaglutide 1.5 MG/ML
- Intervention (Drug): Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Intervention (Drug): Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician
- Intervention (Drug): Dulaglutide 0.75mg subcutaneous injection
- Intervention (Drug): Semaglutide 1.0 mg
- Intervention (Drug): Tirzepatide (Flexible titration)
- Lead sponsor: Zagazig University
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 5b661f50400364b854c58131abb023f3f487805a9d8ea2440f0e16779f83e40c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
